Camidanlumab, also known as HuMax-TAC, represents a cutting-edge therapeutic strategy in the management of certain cancers. This monoclonal antibody specifically binds to tumor necrosis factor , a key cytokine implicated in tumor development and swelling . Initial studies have demonstrated positi